TYNA-1 is being developed as a first line prescription therapy to treat the two leading causes of preventable deaths worldwide – tobacco addiction and obesity.
We believe this proprietary, non-addictive, novel cannabinoid analog will be the first successful treatment to control these diseases. Treatment of the initial indication, smoking cessation including smokeless tobacco and nicotine addiction, will be available in oral pill form.
TYNA-1 is being developed as a safe, small molecule that will readily cross the brain blood barrier. FDA human trials to demonstrate the safety and efficacy of TYNA-1 for the treatment of smoking and smokeless tobacco use are planned for 2023. Additional studies are ongoing at the Johns Hopkins School of Medicine.
